Super-ARMS and ddPCR share the similar accuracy for EGFR mutation detection in plasma biopsy; both methods predicted well the efficacy of EGFR-TKIs by detecting plasma EGFR status.
Translational Oncology (2018) 11, 542–545
Detection of EGFR mutations in ctDNA is an effective method to identify patients who might beneft from frst-line geftinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to geftinib.
www.thelancet.com/respiratory Published online July 12, 2018 //dx.doi.org/10.1016/S2213-2600(18)30264-9
SuperARMS is a promising plasma-based assay for EGFR mutations, including T790M. It might be useful in advanced-stage lung adenocarcinoma patients whose tissue biopsy samples are insufficient for a traditional diagnostic EGFR assay or for patients with a poor performance status.
Clinical Lung Cancer, 2017. https://doi.org/10.1016/j.cllc.2017.12.009
In conclusion, the results from this prospective study indicated the important clinical impact of T790 M detection using plasma samples for NSCLC patients who failed after EGFR-TKI therapy. Well concordance among three assays indicated the feasibility of plasma ctDNA detection. The ddPCR assay had a high sensitivity and might be superior to ARMS and SuperARMS assays.
Pathol. Oncol. Res., 2017. DOI 10.1007/s12253-017-0286-3
ADx-SuperARMS EGFR assay is likely to be a highly sensitive and specific method to noninvasively detect plasma EGFR mutations of patients with advanced lung adenocarcinoma. The EGFR mutations detected by ADx-SuperARMS EGFR assay could predict the efficacy of the treatment with first generation of EGFR-TKIs. Hence, EGFR blood testing with ADxSuperARMS could address the unmet clinical needs.
PLOS ONE, August 22, 2017. https://doi.org/10.1371/journal.pone.0183331.
Histological tissues are preferred for anaplastic lymphoma kinase(ALK) fusion detection in non-small cell lung cancer(NSCLC). The aim of this study was to evaluate the feasibility of cytological sample as an alternative specimen for ALK fusion testing in patients with advanced NSCLC.
LUNG CANCER, DOI: //dx.doi.org/doi:10.1016/j.lungcan. 2016.01.014